Steris Plc (NYSE:STE) has received an average recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $72.33.
Several equities analysts recently commented on the company. TD Securities boosted their target price on Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Raymond James Financial boosted their target price on Steris from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, October 16th. KeyCorp restated an “overweight” rating and set a $101.00 target price (up from $91.00) on shares of Steris in a research report on Thursday, November 2nd. Finally, Zacks Investment Research cut Steris from a “buy” rating to a “sell” rating in a research report on Monday, November 6th.
Steris (NYSE STE) opened at $89.65 on Friday. Steris has a 52-week low of $64.46 and a 52-week high of $93.39. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.18 and a current ratio of 2.80. The company has a market capitalization of $7,651.31, a PE ratio of 23.19 and a beta of 1.28.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd will be issued a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date is Tuesday, November 21st. Steris’s payout ratio is currently 73.81%.
In other news, VP John Adam Zangerle sold 3,650 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $90.50, for a total value of $905,000.00. The disclosure for this sale can be found here. Insiders sold a total of 192,722 shares of company stock valued at $16,913,753 over the last quarter. Company insiders own 2.55% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of STE. Russell Investments Group Ltd. boosted its holdings in shares of Steris by 12.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 148,026 shares of the medical equipment provider’s stock worth $12,064,000 after purchasing an additional 15,991 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in Steris by 3.9% during the 2nd quarter. Great West Life Assurance Co. Can now owns 134,861 shares of the medical equipment provider’s stock valued at $10,964,000 after acquiring an additional 5,077 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Steris by 136.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 95,108 shares of the medical equipment provider’s stock valued at $7,751,000 after acquiring an additional 54,829 shares during the period. World Asset Management Inc boosted its holdings in Steris by 29.4% during the 2nd quarter. World Asset Management Inc now owns 5,407 shares of the medical equipment provider’s stock valued at $441,000 after acquiring an additional 1,230 shares during the period. Finally, TD Asset Management Inc. boosted its holdings in Steris by 0.9% during the 2nd quarter. TD Asset Management Inc. now owns 23,540 shares of the medical equipment provider’s stock valued at $1,919,000 after acquiring an additional 200 shares during the period. Hedge funds and other institutional investors own 89.44% of the company’s stock.
WARNING: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/03/steris-plc-ste-given-consensus-rating-of-buy-by-analysts.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.